BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 26, 2018--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Antony Mattessich, President and Chief Executive Officer
of Ocular Therapeutix, will present at the 2018 Cantor Global Healthcare
Conference on Wednesday, October 3, 2018 at 11:30 AM ET at the
Intercontinental Barclay Hotel in New York, NY.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their Cantor representative.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA® (dexamethasone insert),
has completed Phase 3 clinical development for the treatment of ocular
pain and inflammation following ophthalmic surgery. The New Drug
Application (NDA) for DEXTENZA has a target action date under the FDA
Prescription Drug User Fee Act, or PDUFA, of December 28, 2018. OTX-TP
(travoprost insert) is an intracanalicular insert in Phase 3 clinical
development for the reduction of intraocular pressure in patients with
primary open-angle glaucoma and ocular hypertension. The Company’s
earlier stage assets include OTX-TIC, an extended-delivery travoprost
intracameral implant for the reduction of intraocular pressure in
patients with glaucoma and ocular hypertension, as well as sustained
release intravitreal implants for the treatment of retinal diseases.
These intravitreal implants include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
OTX-IVT, an extended-delivery protein-based anti-vascular endothelial
growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005061/en/
Source: Ocular Therapeutix, Inc.
Chris Brinzey, 339-970-2843
Senior Vice President, Commercial